Urology
Volume 57, Issue 4, Supplement 1 , Pages 46-51 , April 2001

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer

  • Gary J Kelloff

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • Corresponding Author InformationReprint requests: Gary J. Kelloff, MD, Executive Plaza North, EPN306, 5130 Executive Boulevard, Rockville, MD 20852
    • ,
  • Ronald Lieberman

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Vernon E Steele

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Charles W Boone

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Ronald A Lubet

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Levy Kopelovich

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Winfred A Malone

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • James A Crowell

      Affiliations

    • National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA (GJK, RL, VES, CWB, RAL, LK, WAM, JAC)
    • ,
  • Howard R Higley

      Affiliations

    • CCS Associates, Mountain View, California, USA (HRH, CCS)
    • ,
  • Caroline C Sigman

      Affiliations

    • CCS Associates, Mountain View, California, USA (HRH, CCS)

References 

  1. Kelloff GJ, Boone CW, Malone WF, et al.  Introductory remarks (development of chemopreventive agents for prostate cancer). J Cell Biochem. 1992;16(suppl H):1–8
  2. Kelloff GJ, Lieberman RL, Steele VE, et al.  Chemoprevention of prostate cancer (concepts and strategies). Eur Urol. 1999;35:342–350
  3. Greenlee RT, Murray T, Bolden S, et al.  Cancer statistics, 2000. CA Cancer J Clin. 1999;50:7–33
  4. Ross RK, Pike MC, Coetzee GA, et al.  Androgen metabolism and prostate cancer (establishing a model of genetic susceptibility). Cancer Res. 1998;58:4497–4504
  5. Kelloff GJ, Hawk ET, Karp JE, et al.  Progress in clinical chemoprevention. Semin Oncol. 1997;24:1–13
  6. Kelloff GJ, Hawk ET, Crowell JA, et al.  Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology. 1996;10:1471–1480
  7. Kelloff GJ, Boone CW, Crowell JA, et al.  Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials. J Cell Biochem Suppl. 1994;19:1–9
  8. Kelloff GJ, Johnson JK, Crowell JK, et al.  Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:1–10
  9. Gupta S, Ahmad N, Mukhtar H. Prostate cancer chemoprevention by green tea. Semin Urol Oncol. 1999;17:70–76
  10. Gupta S, Ahmad N, Mohan RR, et al.  Prostate cancer chemoprevention by green tea (in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase). Cancer Res. 1999;59:2115–2120
  11. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur Urol. 1999;35(5–6):464–467
  12. Rao KV, Johnson WD, Bosland MC, et al.  Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 1999;59:3084–3089
  13. Steele VE, Holmes CA, Hawk ET, et al.  Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999;8:467–483
  14. Liu X-H, Yao S, Kirshenbaum A, et al.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58:4245
  15. Zhu W, Smith A, Young CY. A non-steroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 1999;140:5451–5454
  16. Stoner E, for The Finasteride Study Group: The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 147: 1298–1302, 1992.
  17. Feigl P, Blumenstein B, Thompson I, et al.  Design of the prostate cancer prevention trial (PCPT). Control Clin Trials. 1995;16:150–163
  18. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res. 1991;51:3610–3611
  19. Urban U, Myers R, Manne U, et al.  Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol. 1999;35:429–438
  20. Kadmon D. Chemoprevention in prostate cancer (the role of difluoromethylornithine (DFMO)). J Cell Biochem. 1992;16(suppl H):122–127
  21. Clark LC, Dalkin B, Krongrad A, et al.  Decreased incidence of prostate cancer with selenium supplementation (results of a double-blind cancer prevention trial). Br J Urol. 1998;81:730–734
  22. Heinonen OP, Albanes D, Virtamo J, et al.  Prostate cancer and supplementation with α-tocopherol and β-carotene (incidence and mortality in a controlled trial). J Natl Cancer Inst. 1998;90:440–446
  23. Aquilina JW, Lipsky JJ, Bostwick ZG. Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst. 1997;89:689–696
  24. Giovannucci EG, Ascherio A, Rimm EB, et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87:1767–1776
  25. Kucuk O, Sakr W, Sarkar FH, et al.  Lycopene supplementation in men with localized prostate cancer (PCa) modulates grade and volume of prostatic intraepithelial neoplasia (PIN) and tumor, level of serum PSA and biomarkers of cell growth, differentiation and apoptosis. Proc Am Assoc Cancer Res. 1999;40:409;[abstract]
  26. Bostwick DG. Prostatic intraepithelial neoplasia (PIN) (current concepts). J Cell Biochem. 1992;16(suppl H):10–19
  27. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol. 1999;35:459–463
  28. Shibata M-A, Jorcyk CL, Liu M-L, et al.  The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol. 1998;26:177–182
  29. Bostwick DG. Target populations and strategies for chemoprevention trials of prostate cancer. J Cell Biochem Suppl. 1994;19:191–196

PII: S0090-4295(00)00940-7

Urology
Volume 57, Issue 4, Supplement 1 , Pages 46-51 , April 2001

Article Tools